LYTIX — Lytix Biopharma AS Share Price
0.000.00%
Last trade - 00:00- NOK268.06m
- NOK217.52m
- NOK3.99m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.22 | ||
| Price to Tang. Book | 5.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 67.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -188.58% | ||
| Return on Equity | -94.3% | ||
| Operating Margin | -2427.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 0.31 | 0 | 0.02 | 1.41 | 3.99 | 6.3 | 13 | 63.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lytix Biopharma AS is a Norway-based company engaged in biotechnology. The Company is involved in development, marketing and sales of pharmaceutical and biotechnology products, as well as related activities. Lytix Biopharma AS developing cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lytix Biopharma molecules kill cancer cells, including resistant cells, and expose their internal components to the immune system. This results in uptake of tumor antigens and activation of tumor antigen-presenting cells, thereby generating a broad and long-lasting systemic T-cell response that overcomes tumor heterogeneity. Lytix Biopharma molecules can work in a wide variety of cancer indications and settings, both as mono- and combination therapies.
Directors
- Knut Eidissen CHM
- Unni Hjelmaas CEO (53)
- Karl-Johan Jakola VCH (59)
- John Svendsen CFD
- Oystein Rekdal CFD
- Wenche Olsen COO
- Anders Fugelli VBD
- Gunnar Saelid OTH
- Havard Ebbestad DRC
- Siri Furst DRC (55)
- Steinar Hoeg DRC
- Alf Lindberg DRC (77)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 25th, 2003
- Public Since
- June 14th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 50,578,121
- Address
- Sandakerveien 138, OSLO, 0484
- Web
- https://www.lytixbiopharma.com/
- Phone
- +47 77675500
- Contact
- Ole Peter Nordby
- Auditors
- Ernst & Young AS
Upcoming Events for LYTIX
Similar to LYTIX
Arcticzymes Technologies ASA
Oslo Stock Exchange
Bergenbio ASA
Oslo Stock Exchange
Circio Holding ASA
Oslo Stock Exchange
Exact Therapeutics AS
Oslo Stock Exchange
Lifecare AS
Oslo Stock Exchange
FAQ
What is the Lytix Biopharma AS share price?
As of Today at 19:13 UTC, shares in Lytix Biopharma AS are trading at NOK5.30. This share price information is delayed by 15 minutes.
How has the Lytix Biopharma AS share price performed this year?
Shares in Lytix Biopharma AS last closed at NOK5.30 and the price had moved by -19.11% over the past 365 days. In terms of relative price strength the Lytix Biopharma AS share price has underperformed the FTSE Global All Cap Index by -24.06% over the past year.
What are the analyst and broker recommendations for Lytix Biopharma AS?
The overall consensus recommendation for Lytix Biopharma AS is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Lytix Biopharma AS dividend yield?
Lytix Biopharma AS does not currently pay a dividend.
Does Lytix Biopharma AS pay a dividend?
Lytix Biopharma AS does not currently pay a dividend.
When does Lytix Biopharma AS next pay dividends?
Lytix Biopharma AS does not currently pay a dividend.
How do I buy Lytix Biopharma AS shares?
To buy shares in Lytix Biopharma AS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lytix Biopharma AS?
As of the previous close price of NOK5.30, shares in Lytix Biopharma AS had a market capitalisation of NOK268.06m.
Where are Lytix Biopharma AS shares listed?
Here are the trading details for Lytix Biopharma AS:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: LYTIX
What kind of share is Lytix Biopharma AS?
Based on an overall assessment of its quality, value and momentum Lytix Biopharma AS is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lytix Biopharma AS share price forecast for 2024?
The analyst consensus target price for shares in Lytix Biopharma AS is NOK12.81. That is 141.7% above the last closing price of NOK5.30.
Analysts covering Lytix Biopharma AS currently have a consensus Earnings Per Share (EPS) forecast of -NOK2.48 for the next financial year.
What is the trend in the Lytix Biopharma AS share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lytix Biopharma AS. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -35.9%.
As of the last closing price of NOK5.30, shares in Lytix Biopharma AS were trading -21.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lytix Biopharma AS PE Ratio?
The Lytix Biopharma AS PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK5.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lytix Biopharma AS?
Lytix Biopharma AS' management team is headed by:
- Knut Eidissen - CHM
- Unni Hjelmaas - CEO
- Karl-Johan Jakola - VCH
- John Svendsen - CFD
- Oystein Rekdal - CFD
- Wenche Olsen - COO
- Anders Fugelli - VBD
- Gunnar Saelid - OTH
- Havard Ebbestad - DRC
- Siri Furst - DRC
- Steinar Hoeg - DRC
- Alf Lindberg - DRC